IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: BIRKELUND et al Application No.: 09/446,677

Filed: March 24, 2000 For: SURFACE EXPOSED PROTEINS FROM CHLAMYDIA

2 3 2000

Art Unit: 1645

Examiner: S. Devi

Washington, D.C.

RECEIVED

VVV 1645. xox Sequence,

Atty.'s Docket: BIRKELUND=1

Date: August 23, 2000

AUG 28 LL.

SECH CENTER JEGGGZET

AUG 30 200

OR

OR

THE COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 Sir:

Transmitted herewith is an [] Amendment [XXX] RESPONSE TO "SEQUENCE LISTING" REQUIREMENT + Sequence Listing + Disk in the above-identified application.

- Small entity status of this application under 37 CFR 1.9 and 1.27 has been established by a verified statement previously submitted
- A verified statement to establish small entity status under 37 CFR 1.9 and 1.27 is enclosed.
- No additional fee is required.
- The fee has been calculated as shown below:

	(Col. 1)		(Col. 2)	(Col. 3)
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR	PRESENT EXTRA EQUALS
TOTAL	*	MINUS	** 20	0
INDEP.	*	MINUS	*** 3	0
FIRST PRESENTATION OF MULTIPLE DEP. CLAIM				

	SIVALL ENTITY			
		RATE	ADDITIONAL FEE	
	х	9	\$	
	х	39	\$	
	+	130	\$	
ADDITIONAL FEE TOTAL		\$		

CMALL ENTITY

OTHER THAN SMALL ENTITY RATE ADDITIONAL FEE 18 \$ 78 \$ 260 \$ TOTAL \$

- If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.
- If the "Highest Number Previously Paid for" IN THIS SPACE is less than 20, write "20" in this space.
- If the "Highest Number Previously Paid for" IN THIS SPACE is less than 3, write "3" in this space.

The "Highest Number Previously Paid For" (total or independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment of the number of claims originally filed.

[XX] Conditional Petition for Extension of Time

If any extension of time for a response is required, applicant requests that this be considered a petition therefor.

It is hereby petitioned for an extension of time in accordance with 37 CFR 1.136(a). The appropriate fee required by 37 CFR 1.17 is calculated as shown below:

	Small Entity	Other Than Small Entity		
	Response Filed Within	Response Filed Within		
	[] First - \$ 55.00	[] First - \$ 110.00		
	[] Second - \$ 190.00	[] Second - \$ 380.00		
	[] Third - \$ 435.00	[] Third - \$ 870.00		
	[] Fourth - \$ 680.00	[] Fourth - \$ 1360.00		
	Month After Time Period Set	Month After Time Period Set		
	[] Less fees (\$) already paid for month(s) extension	n of time on		
[]	Please charge my Deposit Account No. 02-4035 in the amount of \$_	·		
[]	Credit Card Payment Form, PTO-2038, is attached, authorizing paym	nent in the amount of \$		
[]	A check in the amount of \$ is attached (check no.)).		
[XX]	The Commissioner is hereby authorized and requested to charge any	y additional fees which may be required in conne		

ection with this application or credit any overpayment to Deposit Account No. 02-4035. This authorization and request is not limited to payment of all fees associated with this communication, including any Extension of Time fee, not covered by check or specific authorization, but is also intended to include all fees for the presentation of extra claims under 37 CFR §1.16 and all patent processing fees under 37 CFR §1.17 throughout the prosecution of the case. This blanket authorization does not include patent issue fees under 37 CFR §1.18.

BROWDY AND NEIMARK

Attorneys for Applica

Coope

Facsimile: (202) 737-3528 Telephone: (202) 628-5197

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

	1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
X	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
	7. Other:
Аp	plicant Must Provide:
X	An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
	An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
X	A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
Fo	r questions regarding compliance to these requirements, please contact:
Fo	r Rules Interpretation, call (703) 308-4216 r CRF Submission Help, call (703) 308-4212 tentIn Software Program Support (SIRA) Technical Assistance

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE